<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433780</url>
  </required_header>
  <id_info>
    <org_study_id>EZMiM017</org_study_id>
    <nct_id>NCT04433780</nct_id>
  </id_info>
  <brief_title>DORA: The Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV in South Africa</brief_title>
  <acronym>DORA</acronym>
  <official_title>A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Willem Daniel Francois Venter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Witwatersrand, South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study investigating the safety of Doravirine (DOR) in combination with
      Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in women
      of reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based
      antiretroviral therapy on metabolic and neuropsychiatric outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, open label, single-arm, single centre, phase 3, switch study exploring the
      safety of of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil
      Fumarate (TDF) administered over 48 weeks in women of reproductive potential living with
      HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy. The metabolic and
      neuropsychiatric outcomes among women (and their infants) in a representative African female
      population of reproductive potential will be investigated.

      Approximately 100 women aged between 18 and 49 years old will be administered a once-daily,
      fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil
      fumarate 300 mg (DOR/3TC/TDF). The study includes screening and baseline visits, 4 study
      visits from Week 4 to Week 36, and an end of study visit at Week 48.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants with neuropsychiatric adverse events (AEs)</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of participants with neuropsychiatric adverse events (AEs) in 3 pre-specified categories (dizziness, sleep disorders/ disturbances, and altered sensorium) at Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fasting lipids from baseline to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in fasting lipids from baseline to Week 48 assessed using lipid profile blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in weight from baseline to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in weight from baseline to Week 48 assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in body mass index from baseline to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in body mass index from baseline to Week 48 assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in glucose from baseline to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in glucose from baseline to Week 48 assessed using blood test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with detectable plasma HIV-1 RNA levels (≥ 50 copies/mL)</measure>
    <time_frame>At week 24, 48</time_frame>
    <description>The proportion of participants with detectable plasma HIV-1 RNA levels (≥ 50 copies/mL) at weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with neuropsychiatric adverse events (AEs) in 3 pre-specified categories</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of participants with neuropsychiatric adverse events (AEs) in 3 pre-specified categories (dizziness, sleep disorders/ disturbances, and altered sensorium) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose from baseline to week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in glucose from baseline to Week 24 using blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting lipids from baseline to week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in fasting lipids from baseline to Week 24 using lipid profile blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight and from baseline to week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in weight from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body mass index from baseline to week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in body mass index from baseline to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of infants evaluated for HIV-positive tests using HIV DNA polymerase chain reaction test (PCR)</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of infants evaluated for HIV-positive tests using HIV DNA polymerase chain reaction test (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life from baseline</measure>
    <time_frame>At weeks 24, 48</time_frame>
    <description>Changes in quality of life from baseline to Weeks 24 and 48 measured using a traditional clinical, validated quality of life questionairre. Higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median adherence by each adherence measure</measure>
    <time_frame>At weeks 24, 48</time_frame>
    <description>Median adherence by each adherence measure at Weeks 24 and 48 using a validated adherence questionairre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of antiretroviral resistance mutations in participants with virological failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluating the number of antiretroviral resistance mutations that emerge in participants with virological failure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Delstrigo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate</intervention_name>
    <description>DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC</description>
    <arm_group_label>Delstrigo</arm_group_label>
    <other_name>Delstrigo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females, aged 18-49 years and ≥ 40 kg

          -  On a first-line EFV or DTG-containing regimen for at least six months and not more
             than 3 years

          -  Plasma HIV-1 RNA &lt; 50 copies/mL in last 60 days

          -  Calculated creatinine clearance (CrCl) &gt; 50 mL/min (Cockcroft-Gault formula)

          -  Baseline weight measurement available at ART initiation.

        Exclusion Criteria:

          -  Virological failure on any other regimen

          -  Women who are pregnant at the time of the screening or enrolment visits or have had a
             pregnancy gestation ≥ 28 weeks in the preceding 2 years

          -  Active tuberculosis and/or are on antituberculosis therapy at the time of the
             screening or enrolment visits

          -  Taking (and cannot discontinue) prohibited concomitant medications listed in protocol
             at least two weeks prior to the enrolment visit and for the duration of the study
             period (see potential drug interactions section for list).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female HIV-positive participants of reproductive potential age</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simiso Sokhela</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ezintsha, a subdivision of Wits Reproductive Health and HIV Institute (Wits RHI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nomathemba Chandiwana, MBBCh</last_name>
    <phone>+27 1 1358 5651</phone>
    <email>nchandiwana@wrhi.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joana Woods</last_name>
    <phone>+27113585300</phone>
    <email>jwoods@wrhi.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <phone>+27113585500</phone>
      <email>ssokhela@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Nonkululeko Mashabane, BPharm</last_name>
      <phone>+27113585543</phone>
      <email>nmashabane@wrhi.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nomathemba Chandiwana, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joana Woods, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnyside Office Park</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Bronwyn Bosch, MBBCh</last_name>
      <phone>+27113585300</phone>
      <email>bbosch@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Godspower Akpomiemie, MPH</last_name>
      <phone>+2711358 5370</phone>
      <email>gakpomiemie@wrhi.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nomathemba Chandiwana, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joana Woods, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Witwatersrand, South Africa</investigator_affiliation>
    <investigator_full_name>Willem Daniel Francois Venter</investigator_full_name>
    <investigator_title>Divisional Director of Ezintsha</investigator_title>
  </responsible_party>
  <keyword>Doravirine</keyword>
  <keyword>Delstrigo</keyword>
  <keyword>DOR/3TC/TDF</keyword>
  <keyword>Women of reproductive potential</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

